Your browser doesn't support javascript.
loading
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease.
Hu, Yan; Cho, Min; Sachdev, Pallavi; Dage, Jeffrey; Hendrix, Suzanne; Hansson, Oskar; Bateman, Randall J; Hampel, Harald.
Afiliación
  • Hu Y; Eisai Inc., Nutley, NJ, USA.
  • Cho M; Eisai Inc., Nutley, NJ, USA.
  • Sachdev P; Eisai Inc., Nutley, NJ, USA.
  • Dage J; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Hendrix S; Pentara Corporation, Millcreek, UT, USA.
  • Hansson O; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
  • Bateman RJ; Department of Neurology, Washington University of St. Louis, St. Louis, MO, USA; The Tracy Family SILQ Center, Washington University School of Medicine, Saint Louis, MO, USA.
  • Hampel H; Eisai Inc., Nutley, NJ, USA. Electronic address: harald_hampel@eisai.com.
Med ; 2024 Sep 04.
Article en En | MEDLINE | ID: mdl-39255800
ABSTRACT
Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajectory. Imaging and fluid biomarkers are becoming increasingly important in the clinical development of AD therapeutics. This review focuses on the evidence of fluid biomarkers from recent amyloid-ß-targeting clinical trials, summarizing biomarker data across 12 trials. It further proposes a simple framework to put biomarker guidance in the context of amyloid-pathway-targeted disease modification, delineates factors that impact biomarker data in clinical trials, and highlights knowledge gaps and future directions. Increased knowledge and data on biomarkers in the context of disease progression and disease modification will help to better design future AD trials and guide the clinical management of patients on AD-modifying therapies, bringing us closer to the implementation of precision medicine in AD.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Med Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos